---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-193238"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:53:32.695220+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M

## Summary
- Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.
- Upfront $210M; up to $100M development/regulatory milestones and $220M commercial milestones.
- Royalties on ex-US net sales: mid-teens to low-twenties percent.
- Cash runway extended by at least 12 months; expects funding into 2030 under current plan.

## SEC filing metadata
- accession: 0001193125-25-193238
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/0001193125-25-193238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-193238
- JSON: https://secwatch.observer/filing/0001193125-25-193238.json
- Plain text: https://secwatch.observer/filing/0001193125-25-193238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.